160 related articles for article (PubMed ID: 24651764)
1. Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer.
Zhang H; Wei Q; Liu R; Qi S; Liang P; Qi C; Wang A; Sheng B; Li L; Xu Y
PLoS One; 2014; 9(3):e91069. PubMed ID: 24651764
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study.
Meng F; Luo C; Hu Y; Yin M; Lin M; Lou G; Zhou R
Int J Gynecol Pathol; 2010 Nov; 29(6):587-93. PubMed ID: 20881850
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer.
Xiao M; Jia S; Wang H; Wang J; Huang Y; Li Z
J Cancer Res Clin Oncol; 2013 Apr; 139(4):661-7. PubMed ID: 23292099
[TBL] [Abstract][Full Text] [Related]
4. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.
Yang H; Xiong FX; Lin M; Yang Y; Nie X; Zhou RL
J Cancer Res Clin Oncol; 2010 Feb; 136(2):275-81. PubMed ID: 19690886
[TBL] [Abstract][Full Text] [Related]
5. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
6. LAPTM4B-35, a cancer-related gene, is associated with poor prognosis in TNM stages I-III gastric cancer patients.
Cheng X; Zheng Z; Bu Z; Wu X; Zhang L; Xing X; Wang X; Hu Y; Du H; Li L; Li S; Zhou R; Wen XZ; Ji JF
PLoS One; 2015; 10(4):e0121559. PubMed ID: 25849595
[TBL] [Abstract][Full Text] [Related]
7. Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer.
Zhang H; Qi C; Wang A; Yao B; Li L; Wang Y; Xu Y
J Exp Clin Cancer Res; 2013 Oct; 32(1):77. PubMed ID: 24422979
[TBL] [Abstract][Full Text] [Related]
8. Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer.
Meng F; Tan S; Liu T; Song H; Lou G
Tumour Biol; 2016 Apr; 37(4):4849-55. PubMed ID: 26526574
[TBL] [Abstract][Full Text] [Related]
9. LAPTM4B overexpression is a novel independent prognostic marker for metastatic ovarian tumors.
Yin M; Lou C; Zhang W; Meng F; Zhang H; Ning X; Zhou R; Dong X; Lou G
Int J Gynecol Cancer; 2012 Jan; 22(1):54-62. PubMed ID: 22193644
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of LAPTM4B is correlated with tumor angiogenesis and poor prognosis in non-small cell lung cancer.
Tang H; Tian H; Yue W; Li L; Li S; Gao C; Si L; Qi L; Lu M
Med Oncol; 2014 Jun; 31(6):974. PubMed ID: 24816841
[TBL] [Abstract][Full Text] [Related]
11. LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma.
Meng FL; Yin MZ; Song HT; Yang H; Lou G; Zhou RL
Int J Gynecol Cancer; 2010 Jul; 20(5):745-50. PubMed ID: 20966643
[TBL] [Abstract][Full Text] [Related]
12. Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients.
Li S; Wang L; Meng Y; Chang Y; Xu J; Zhang Q
Oncotarget; 2017 Jun; 8(25):41282-41293. PubMed ID: 28476037
[TBL] [Abstract][Full Text] [Related]
13. Lysosomal-associated protein transmembrane 4 Beta-35 overexpression is a novel independent prognostic marker for gastric carcinoma.
Liu L; Xu X; Jing L; Zhou G; Cao Z; Han Y; Zhou R
PLoS One; 2015; 10(2):e0118026. PubMed ID: 25689860
[TBL] [Abstract][Full Text] [Related]
14. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer.
Guo J; Wang M; Wang Z; Liu X
PLoS One; 2016; 11(8):e0158667. PubMed ID: 27537362
[TBL] [Abstract][Full Text] [Related]
17. Elevated lysosome-associated protein transmembrane-4β-35 is an independent prognostic marker in pancreatic carcinoma.
Zhang G; Liang Y; Huang Y; Chen Y; Zhou R
J Int Med Res; 2012; 40(4):1275-83. PubMed ID: 22971479
[TBL] [Abstract][Full Text] [Related]
18. LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma.
Yang Y; Yang H; McNutt MA; Xiong F; Nie X; Li L; Zhou R
Oncol Rep; 2008 Nov; 20(5):1077-83. PubMed ID: 18949404
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of LIMK1 expression in prostate cancer is correlated with poor pathological features, lymph node metastases and biochemical recurrence.
Huang JB; Wu YP; Lin YZ; Cai H; Chen SH; Sun XL; Li XD; Wei Y; Zheng QS; Xu N; Xue XY
J Cell Mol Med; 2020 Apr; 24(8):4698-4706. PubMed ID: 32168432
[TBL] [Abstract][Full Text] [Related]
20. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
